Because of its high sensitivity, good specificity, flexible detection ability and reliability in prediction, Ki67 has been accepted as an ideal biomarker for prognostic assessment in the clinical setting of breast and neuroendocrine cancers; however, whether Ki67 is a prognostic marker in NSCLC remains to be elucidated. This evidence concerns the gene MKI67 and neuroendocrine carcinoma.